Article section

Article title
Contributor
Abstract
About article
DOI
Citation style
Copyright
Open access
References
Research Article

IL-17A and IL-6 as Key Mediators of Immune Dysregulation and Systemic Inflammation in Psoriasis

Authors

  • Noor H. Al-Mousawi Department of Pathological Analysis, College of Science, Wasit University, Iraq https://orcid.org/0009-0009-5457-8506

    nalmaksosy@uowasit.edu.iq

  • Tamarah H. Ahmed Department of Physiology, Biochemistry and Pharmacology, College of Veterinary Medicine, Wasit University, Iraq

Abstract

The psoriasis, which is a chronic inflammatory skin disease, in addition is immune-mediated, is also characterized by hyperproliferation of keratinocytes and infiltration of activated immune cells. Besides, psoriatic inflammation pathogenesis and persistence are primarily connected with the imbalance of cytokines, IL-6, and IL-17A. Thus, early detection of elevated cytokine levels may be used in the therapeutic monitoring and disease evaluation. The current study was aimed to compare the IL-6 and IL-17A diagnostic performance of psoriasis patients that of healthy people. Eighty participants were included in this study, 30 controls (matched in age and sex), whereas 50 cases of psoriasis patients. The lab results of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), also IL-6, and IL-17A by means of ELISA. It was found that the mean serum levels of IL-6 and IL-17A were significantly increased in patients with psoriasis compared to controls (p < 0.001). In addition, the analysis results of ROC showed that both cytokines possess high sensitivity and specificity values, which implies good diagnostic capacity. Therefore, findings suggest that IL-6 and IL-17A can be effective immunological markers of assessing the inflammatory activity and also might be utilized in the early diagnosis and treatment of psoriasis.

Keywords:

Cytokines ESR hs-CRP IL-17A IL-6 Immune Biomarkers Inflammation

Article information

Journal

Journal of Medical Science, Biology, and Chemistry

Volume (Issue)

2(1), (2025)

Pages

181-186

Published

27-06-2025

How to Cite

Al-Mousawi, N. H., & Ahmed, T. H. (2025). IL-17A and IL-6 as Key Mediators of Immune Dysregulation and Systemic Inflammation in Psoriasis. Journal of Medical Science, Biology, and Chemistry, 2(1), 181-186. https://doi.org/10.69739/jmsbc.v2i1.802

References

Brembilla, N. C., & Boehncke, W. H. (2023). Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Frontiers in immunology, 14, 1186455.

Brembilla, N. C., & Boehncke, W. H. (2023). Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Frontiers in immunology, 14, 1186455.‏

De Santis, M., Tonutti, A., Isailovic, N., Motta, F., Rivara, R. M., Ragusa, R.,. .. & Selmi, C. (2024). Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis. Frontiers in Immunology, 15, 1455134.‏

Hołdrowicz, A., & Żebrowska, A. (2025). Molecular Link Between Psoriasis and Depression Update on Pathophysiology. International Journal of Molecular Sciences, 26(6), 2467.

Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023). The IL-17 family in diseases: from bench to bedside. Signal transduction and targeted therapy, 8(1), 402.‏

Hüning, S. (2022). Mycosis fungoides: Ist das Therapieansprechen von Brentuximab Vedotin abhängig von der CD30-Expression?. Kompass Dermatologie, 10(1), 12-13.‏

Ishchenko, A., Van Mechelen, M., Pazmino, S., Storms, L., Neerinckx, B., Verschueren, P., ... & de Vlam, K. (2025). Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein. RMD open, 11(3).‏

‏Kar, B. R., Sathishkumar, D., Tahiliani, S., Parthasarathi, A., Neema, S., Ganguly, S., & Thomas, J. (2024). Biomarkers in Psoriasis: The Future of Personalised Treatment. Indian Journal of Dermatology, 69(3), 256-263.‏

Krueger, J. G., Eyerich, K., Kuchroo, V. K., Ritchlin, C. T., Abreu, M. T., Elloso, M. M.,. .. & McInnes, I. B. (2024). IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Frontiers in immunology, 15, 1331217.

Lawrence‐Wolff, K. M., Higgs, J. B., Young‐McCaughan, S., Mintz, J., Foa, E. B., Resick, P. A.,. .. & STRONG STAR Consortium. (2023). Prevalence of Fibromyalgia Syndrome in Active‐Duty Military Personnel. Arthritis care & research, 75(3), 667-673.‏

Lebwohl, M. G., Carvalho, A., Asahina, A., Zhang, J., Fazeli, M. S., Kasireddy, E.,. .. & Thaši, D. (2025). Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis. Dermatology and Therapy, 1-24.‏

Lebwohl, M. G., Carvalho, A., Asahina, A., Zhang, J., Fazeli, M. S., Kasireddy, E.,. .. & Thaši, D. (2025). Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis. Dermatology and Therapy, 1-24.‏

Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T.,. .. & Tai, Z. (2025). Interventions in cytokine signaling: novel horizons for psoriasis treatment. Frontiers in Immunology, 16, 1573905.‏

Lopez, D. V., & Kongsbak‐Wismann, M. (2022). Role of IL‐22 in homeostasis and diseases of the skin. Apmis, 130(6), 314-322.‏

Matei-Man, A. M., Vesa, Ș. C., Pușcaș, A. D., Orăsan, M. S., Homorozeanu, B., Candrea, E., & Mocan, T. (2025). Assessment of TNF-α, IL-12/23, and IL-17 in Psoriasis: Only TNF-α Reflects Clinical Response After 12 Weeks of Biologic Treatment. Current Issues in Molecular Biology, 47(5), 368.‏

Melikoğlu, M., & Pala, E. (2023). Systemic Immune-inflammation index as a biomarker of psoriasis severity. Archives of Basic and Clinical Research.‏

Merzel Šabović, E. K., Kraner Šumenjak, T., Božič Mijovski, M., & Janić, M. (2025). Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study. Immunologic research, 73(1), 28.‏

Mills, K. H. (2023). IL-17 and IL-17-producing cells in protection versus pathology. Nature Reviews Immunology, 23(1), 38-54.‏

Paroli, M., Gioia, C., Accapezzato, D., & Caccavale, R. (2025). Demographic Characteristics and Inflammatory Biomarker Profile in Psoriatic Arthritis Patients with Comorbid Fibromyalgia: A Cross-Sectional Study. Medicina, 61(6), 1050.‏

Solak, B., & Kara, R. Ö. (2024). Assessing systemic inflammatory markers in psoriasis: A retrospective study. Tropical Medicine & International Health, 29(11), 971-978.‏

Wang, Y., Liu, T., Li, S., Tang, S., Lin, P., Ding, Y., ... & Fang, H. (2022). Efficacy and safety of baricitinib in patients with refractory alopecia areata. Dermatologic Therapy, 35(12), e15845.‏

Xiong, H., & Yu, Z. (2025). Association between systemic inflammation indicators and psoriasis: a cross-sectional study from NHANES. Frontiers in Immunology, 16, 1556487.‏

Yousaf, I., & Yousaf, A. (2025). Advanced Nanostructured Topical Therapeutics for Psoriasis: Strategic Synthesis, Multimodal Characterization, and Preliminary Pharmacodynamic Profiling. arXiv preprint arXiv:2506.01572.‏

Zhao, H., Shang, L., Zhang, Y., Liang, Z., Wang, N., Zhang, Q.,. .. & Luo, J. (2024). IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function. Frontiers in Immunology, 15, 1344963.‏

Downloads

Views

0

Downloads

0